Bicycle Toxin Conjugates (BTCs)
Various Solid Tumors
Preclinical/DiscoveryActive
Key Facts
About Bicycle Therapeutics
Bicycle Therapeutics aims to become a world-leading solid tumor medicines company by leveraging its proprietary Bicycle® platform to create precision-guided therapeutics. Its core technology enables the rapid discovery and development of constrained peptides with high affinity and selectivity for challenging targets. The company is progressing multiple clinical-stage oncology assets and has established creative collaborative relationships to expand its technology into anti-infective, cardiovascular, and CNS diseases.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Individualized mRNA Cancer Immunotherapies | BioNTech | Phase 2/3 |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved |
| IMA30X Series (ACTengine®) | Immatics | Pre-clinical |
| RP2 / RP2 + nivolumab | Replimune | Phase 1 |
| Bicycle Radio Conjugates (BRCs) | Bicycle Therapeutics | Preclinical/Discovery |
| Micvotabart pelidotin (MICVO) | Pyxis Oncology | Phase 1 |
| OST-tADC Platform | OS Therapies | Pre-clinical |